XJPX
6849
Market cap1.63bUSD
Oct 09, Last price
1,643.00JPY
1D
2.40%
1Q
9.57%
Jan 2017
-36.49%
Name
Nihon Kohden Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nihon Kohden Corporation, founded in 1951 and headquartered in Tokyo, Japan, is a global leader in healthcare technology. The company’s core operations encompass the research, development, manufacturing, sales, repair, and maintenance of advanced medical electronic equipment, serving markets across Japan, the Americas, Europe, Asia, and other international regions. Its extensive product range features sophisticated physiological measurement instruments, including electroencephalographs (EEGs), electrocardiographs (ECGs), evoked potential and electromyogram (EMG) systems, and polygraphs for cardiac catheterization laboratories. These offerings are integrated with diagnostic information systems and supported by essential consumables like recording papers, electrodes, and catheters, along with comprehensive maintenance services. Nihon Kohden also delivers cutting-edge patient monitoring solutions, such as central, bedside, and wireless monitors, alongside remote access software. These are seamlessly linked with clinical information systems and provided with associated disposables, including various electrodes and sensors. The company's therapeutic device portfolio includes critical equipment like defibrillators (including automated external defibrillators or AEDs), ventilators, pacemakers, anesthesia machines, and cochlear implants. Necessary consumables, such as AED pads and batteries, and related services are also supplied for these products. Furthermore, Nihon Kohden offers other specialized medical apparatus, such as hematology and clinical chemistry analyzers, ultrasound diagnostic equipment, and tools for research purposes. These are accompanied by consumables like test reagents, installation services, and ongoing maintenance. Beyond its primary focus on medical devices, the corporation also participates in insurance brokerage and technology licensing.
Key people
Kenji Furukawa
Managing Executive Officer, Chief Human Capital Officer, Deputy Chief Director of Global Business Administration, Director of Human Resources · since 2024
Eiichi Tanaka
Senior Managing Executive Officer, Chief Operating Officer, Director · since 2025
Yoshiyuki Fujita
Senior Executive Officer, Chief Quality & Regulatory Officer, Chief Director of Quality Administration · since 2024
Toshihiko Hiraoka
Senior Executive Officer, Chief Regional Officer - Japan (CRO-J) · since 2024
Hirohiko Ikeya
Senior Executive Officer, Chief Technology Officer, Chief Director of Technology Development · since 2024
Kaoru Imajo
Senior Executive Officer, Chief Innovation Officer, CEO of Subsidiary · since 2025
Yutaka Inano
Senior Executive Officer, Chief Manufacturing Officer (CMO), Chief Director of Production, Senior Director of SCM, President of Subsidiary · since 2024
Kazuomi Shimoda
Senior Executive Officer, Chief Director of Product Business, Chief Business Development Officer · since 2024
Hironori Asa
Executive Officer, Chief Director of Domestic Business · since 2024
Hiroko Hagiwara
Executive Officer, Senior Director of Clinical Development & RA · since 2021
Fumito Horiuchi
Executive Officer, Chief Director of Customer Service · since 2025
Fumio Izumida
Executive Officer, Senior Director of Business Strategy · since 2022
Masahiko Kumakura
Executive Officer, Chief Director of Customer Service · since 2020
Seiji Miyazaki
Executive Officer, Chief Director of China Business · since 2023
Shuhei Morinaga
Executive Officer, Deputy Chief Director of America Business · since 2020
Naoto Nishii
Executive Officer, Chief Director of Business Strategy · since 2025
Yoshinori Obara
Executive Officer, Senior Director of Solutions Business · since 2024
Tsutomu Wakabayashi
Executive Officer, Chief Director of Technology Strategy · since 2023
Eri Watanabe
Executive Officer, Deputy Chief Director of Global Business Administration, Director of Accounting · since 2021
Keiichiro Yoshizawa
Executive Officer, Chief Director of North American Business, CEO of Subsidiary · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||